Viatris
Provides access to medicines, advances sustainable operations, develops innovative solutions and leverages collective expertise to connect more people to more products.
- Healthcare
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
* | N/A | Merger | |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 50 % | (9 %) | (5 %) | (4 %) | (6 %) | 2 % | 1 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 2 % | 21 % | 24 % | 22 % | 29 % | 30 % | 31 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (7 %) | 13 % | - | (4 %) | (22 %) | 1 % | 3 % |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 4 % | 4 % | 5 % | 5 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Viatris is a global pharmaceutical company formed through the merger of Mylan and Pfizer's Upjohn business. The company focuses on providing access to medicines, advancing sustainable operations, and improving patient health. Viatris has a diverse portfolio of products that includes branded and generic drugs, complex generics, and biosimilars. The company's business model is centered on leveraging its global commercial infrastructure and supply chain to deliver high-quality medicines to patients in more than 165 countries.
Viatris's revenue is generated through the sale of its pharmaceutical products. The company's key therapeutic areas include cardiovascular, infectious diseases, immunology, and oncology. Viatris is also committed to addressing public health challenges, such as the growing burden of non-communicable diseases. The company's strategy involves organic growth through its existing product portfolio and inorganic growth through strategic partnerships and acquisitions.
Keywords: pharmaceuticals, generic drugs, biosimilars, branded drugs, global healthcare, Mylan, Pfizer, Upjohn, non-communicable diseases, supply chain
Tech stack
Investments by Viatris
Edit
